JP2016520599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520599A5 JP2016520599A5 JP2016515625A JP2016515625A JP2016520599A5 JP 2016520599 A5 JP2016520599 A5 JP 2016520599A5 JP 2016515625 A JP2016515625 A JP 2016515625A JP 2016515625 A JP2016515625 A JP 2016515625A JP 2016520599 A5 JP2016520599 A5 JP 2016520599A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- use according
- protein
- human origin
- egf domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 239000002158 endotoxin Substances 0.000 claims 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000607528 Aeromonas hydrophila Species 0.000 claims 2
- 241000588923 Citrobacter Species 0.000 claims 2
- 241000588697 Enterobacter cloacae Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 241000588655 Moraxella catarrhalis Species 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 241000588770 Proteus mirabilis Species 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 241000607715 Serratia marcescens Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310206726 | 2013-05-29 | ||
| CN201310206726.6 | 2013-05-29 | ||
| CN201410182727.6A CN104211799B (zh) | 2013-05-29 | 2014-04-30 | 人源egf结构域蛋白及其应用 |
| CN201410182727.6 | 2014-04-30 | ||
| PCT/CN2014/077789 WO2014190860A1 (zh) | 2013-05-29 | 2014-05-19 | 人源egf结构域蛋白及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520599A JP2016520599A (ja) | 2016-07-14 |
| JP2016520599A5 true JP2016520599A5 (https=) | 2017-06-29 |
| JP6503342B2 JP6503342B2 (ja) | 2019-04-17 |
Family
ID=51987987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515625A Active JP6503342B2 (ja) | 2013-05-29 | 2014-05-19 | ヒト起源ｅｇｆドメインタンパク質及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9833497B2 (https=) |
| EP (1) | EP3006460B1 (https=) |
| JP (1) | JP6503342B2 (https=) |
| CN (2) | CN104211799B (https=) |
| WO (1) | WO2014190860A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201691749A1 (ru) * | 2014-02-28 | 2016-12-30 | 3Б Фармасьютикалз Гмбх | Пептиды и способы применения |
| WO2015153402A1 (en) * | 2014-04-03 | 2015-10-08 | The Regents Of The University Of California | Peptide fragments of netrin-1 and compositions and methods thereof |
| AU2018293925B2 (en) * | 2017-06-30 | 2024-06-13 | Adelaide university | A method of treatment |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| WO2022217037A1 (en) * | 2021-04-09 | 2022-10-13 | Board Of Regents, The University Of Texas System | Compositions and methods for treatment of chronic lung diseases |
| EP4198045A1 (en) * | 2021-12-16 | 2023-06-21 | Université de Lille | Antimicrobial peptides, variants and chemical analogues thereof and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450127A1 (en) * | 2001-06-14 | 2002-12-27 | Shujian Wu | Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue |
| CA2528239A1 (en) * | 2003-06-05 | 2004-12-16 | Canadian Blood Services | Mutants of the factor vii epidermal growth factor domain |
| WO2005111070A2 (en) * | 2004-05-13 | 2005-11-24 | Regents Of The University Of Minnesota | Mucin3 egf-like domains |
| US20110212108A1 (en) * | 2008-05-09 | 2011-09-01 | The Regents Of The University Of California | Neuregulin/erbb signaling and integrin |
| WO2010006136A2 (en) * | 2008-07-09 | 2010-01-14 | Mayo Foundation For Medical Education And Research | Adenovirus targeting |
| JP5909180B2 (ja) * | 2009-06-25 | 2016-04-26 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | キメラ第ｖｉｉ因子分子 |
| TW201217527A (en) * | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
-
2014
- 2014-04-30 CN CN201410182727.6A patent/CN104211799B/zh active Active
- 2014-05-19 US US14/894,417 patent/US9833497B2/en active Active
- 2014-05-19 EP EP14803694.0A patent/EP3006460B1/en active Active
- 2014-05-19 WO PCT/CN2014/077789 patent/WO2014190860A1/zh not_active Ceased
- 2014-05-19 JP JP2016515625A patent/JP6503342B2/ja active Active
- 2014-05-19 CN CN201480042519.4A patent/CN105683216B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520599A5 (https=) | ||
| Lopes et al. | The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance | |
| Bitrus et al. | Staphylococcus aureus: A review of antimicrobial resistance mechanisms | |
| Masso-Silva et al. | Antimicrobial peptides from fish | |
| JP2012530509A5 (https=) | ||
| CY1123138T1 (el) | Κυτταροτοξικες πρωτεϊνες που περιλαμβανουν περιοχες δεσμευσης στοχευσης-κυtταρων και περιοχες α υπομοναδας τοξινης shiga για επιλεκτικη θανατωση συγκεκριμενων κυτταρικων τυπων | |
| Ioannou et al. | Antimicrobial peptides in infectious diseases and beyond—a narrative review | |
| MX2020006098A (es) | Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. | |
| BR112019011660A2 (pt) | composições de bacteriófagos que compreendem fagos antibacterianos respiratórios e métodos de uso das mesmas | |
| EA201270774A1 (ru) | Способ уменьшения биопленок | |
| EA201990551A1 (ru) | Антибиотические соединения | |
| GB201018518D0 (en) | Novel endolysin | |
| AU2011206532A8 (en) | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) | |
| JP2014500714A5 (https=) | ||
| EA201990091A1 (ru) | Способ получения и очистки натриевой соли гиалуроновой кислоты | |
| EP4606375A3 (en) | Antibacterial compounds | |
| EP4477272A3 (en) | Polymyxin derivatives as antimicrobial compounds | |
| WO2016210370A3 (en) | Synthetic peptide compounds and methods of use | |
| MX2019014935A (es) | Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos. | |
| PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
| CL2017002668A1 (es) | Tratamiento de infecciones bacterianas en la acuicultura | |
| EA201991233A1 (ru) | Новый эндолизин | |
| JP2018523675A5 (https=) | ||
| MX2019007902A (es) | Composiciones para el tratamiento de seres humanos. | |
| JP2016521685A5 (https=) |